Summary

KEY FINDINGS
The North America Alzheimer’s disease therapeutics & diagnostics market is estimated to develop with a CAGR of 5.60% over the forecast period 2024-2032. The market was valued at $2941.34 million in 2023 and is expected to reach a revenue of $4825.00 million by 2032.
MARKET INSIGHTS
The North America Alzheimer's disease therapeutics & diagnostics market is expanding due to several key factors. The increase in Alzheimer's disease cases, coupled with advancements in diagnostic technologies, is driving market growth. As the elderly population continues to expand, there is a rising demand for more effective diagnostic tools and therapeutics. Moreover, the growth in the number of drugs under development, including those targeting the underlying causes of Alzheimer's, is enhancing treatment options and fueling market expansion. These factors collectively contribute to a more dynamic and rapidly evolving Alzheimer's disease market in North America.
REGIONAL ANALYSIS
The North America Alzheimer’s disease therapeutics & diagnostics market growth evaluation entails the assessment of the United States and Canada.
The US is home to several leading pharmaceutical companies and research institutions focused on developing innovative therapies and diagnostic tools. Advancements in early detection techniques, such as biomarker testing and imaging technologies, are improving the ability to diagnose Alzheimer’s at earlier stages, which, in turn, boosts the demand for therapeutics. Additionally, increased funding for Alzheimer’s research and public health initiatives is supporting market growth and enhancing treatment options for patients.
In Canada, the Alzheimer’s disease therapeutics & diagnostics market is experiencing steady growth as the elderly population expands and awareness of Alzheimer’s care improves. The Canadian healthcare system plays a pivotal role in ensuring broad access to emerging diagnostic tools and treatment options, contributing to the market’s development. Canadian research institutions are also at the forefront of innovative studies, focusing on novel drug candidates and non-invasive diagnostic methods. As both countries continue to address the challenges posed by an aging population, the Alzheimer’s disease therapeutics & diagnostics market in North America is poised for continued expansion.
SEGMENTATION ANALYSIS
The North America Alzheimer’s disease therapeutics & diagnostics market segmentation includes the market by product. The product segment is further differentiated into therapeutics (including cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics) as well as diagnostics (including brain imaging, CSF test for Alzheimer’s disease, and other diagnostics).
Cholinesterase inhibitors are a primary class of therapeutics used in the treatment of Alzheimer's disease, aimed at alleviating symptoms by increasing the levels of acetylcholine. Further, this neurotransmitter is often depleted in patients with Alzheimer's. Acetylcholine plays a crucial role in memory and learning processes, and its reduction is associated with cognitive decline in Alzheimer's disease. Cholinesterase inhibitors work by blocking the enzyme acetylcholinesterase, which breaks down acetylcholine, thereby enhancing its availability and improving communication between nerve cells. Drugs like donepezil, rivastigmine, and galantamine fall under this category and are commonly prescribed to patients with mild to moderate Alzheimer's disease to help manage cognitive symptoms and slow disease progression.
Although cholinesterase inhibitors do not cure Alzheimer's, they are effective in improving symptoms or slowing their progression in some individuals. These medications may also help in stabilizing cognitive function and enhancing the ability to perform daily activities. However, their effectiveness varies among patients, and they can be associated with side effects such as nausea, diarrhea, insomnia, and muscle cramps. As part of a comprehensive Alzheimer's treatment plan, cholinesterase inhibitors are often used in combination with other therapies, such as NMDA receptor antagonists, to address a broader range of symptoms and enhance patient outcomes.
COMPETITIVE INSIGHTS
Some of the leading players in the North America Alzheimer’s disease therapeutics & diagnostics market include Baxter International Inc, Allergan PLC (acquired by AbbVie), Biogen Inc, Cognoptix Inc, etc.
Baxter International Inc, headquartered in Deerfield, Illinois, United States, is a global healthcare company specializing in medical devices, pharmaceuticals, and biotechnology. Founded in 1931, it focuses on critical care therapies, including renal and hospital care. The company operates in over 100 countries and is known for its innovative healthcare solutions. Baxter is committed to improving patient outcomes through advanced medical technologies and sustainable practices.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON THE NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. GROWING R&D INVESTMENT IN THE BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.5.2. INCREASING DEMAND FOR THE PERSONALIZED MEDICINES
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS
3.2. KEY DRIVERS
3.2.1. INCREASE IN ALZHEIMER’S DISEASE CASES
3.2.2. ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES
3.2.3. GROWTH IN THE NUMBER OF DRUGS UNDER DEVELOPMENT
3.2.4. EXPANSION OF THE ELDERLY POPULATION
3.3. KEY RESTRAINTS
3.3.1. LIMITED AVAILABILITY OF SURROGATE MARKERS
3.3.2. LATE-STAGE DRUG FAILURES
3.3.3. STRICT GOVERNMENT REGULATIONS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. ADVANCEMENTS IN IN-VITRO DIAGNOSTIC TECHNIQUES
4.1.2. USAGE OF COMPUTED TOMOGRAPHY IN THE DIAGNOSTICS OF ALZHEIMER’S DISEASE
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR NORTH AMERICA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. R&D
4.6.2. RAW MATERIAL
4.6.3. MANUFACTURING
4.6.4. WHOLESALERS/DISTRIBUTORS/RETAILERS
4.6.5. END-USER
4.7. KEY BUYING CRITERIA
4.7.1. PRICE
4.7.2. EFFICIENCY
4.7.3. SAFETY
4.8. ETYMOLOGY OF THE NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
4.9. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
5. MARKET BY PRODUCT
5.1. THERAPEUTICS
5.1.1. CHOLINESTERASE INHIBITORS
5.1.2. NMDA RECEPTOR ANTAGONISTS
5.1.3. OTHER THERAPEUTICS
5.2. DIAGNOSTICS
5.2.1. BRAIN IMAGING
5.2.2. CSF TEST FOR ALZHEIMER’S DISEASE
5.2.3. OTHER DIAGNOSTICS
6. GEOGRAPHICAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. MARKET SIZE & ESTIMATES
6.1.2. NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET DRIVERS
6.1.3. NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET CHALLENGES
6.1.4. NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET REGULATORY FRAMEWORK
6.1.5. KEY PLAYERS IN NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
6.1.6. COUNTRY ANALYSIS
6.1.6.1. UNITED STATES
6.1.6.1.1. UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
6.1.6.2. CANADA
6.1.6.2.1. CANADA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
7. COMPETITIVE LANDSCAPE
7.1. KEY STRATEGIC DEVELOPMENTS
7.1.1. MERGERS & ACQUISITIONS
7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
7.1.3. PARTNERSHIPS & AGREEMENTS
7.1.4. BUSINESS EXPANSIONS & DIVESTITURES
7.2. COMPANY PROFILES
7.2.1. BAXTER INTERNATIONAL INC
7.2.1.1. COMPANY OVERVIEW
7.2.1.2. PRODUCT LIST
7.2.1.3. STRENGTHS & CHALLENGES
7.2.2. ALLERGAN PLC (ACQUIRED BY ABBVIE)
7.2.2.1. COMPANY OVERVIEW
7.2.2.2. PRODUCT LIST
7.2.2.3. STRENGTHS & CHALLENGES
7.2.3. BIOGEN INC
7.2.3.1. COMPANY OVERVIEW
7.2.3.2. PRODUCT LIST
7.2.3.3. STRENGTHS & CHALLENGES
7.2.4. COGNOPTIX INC
7.2.4.1. COMPANY OVERVIEW
7.2.4.2. PRODUCT LIST
7.2.4.3. STRENGTHS & CHALLENGES
7.2.5. ELI LILLY AND COMPANY
7.2.5.1. COMPANY OVERVIEW
7.2.5.2. PRODUCT LIST
7.2.5.3. STRENGTHS & CHALLENGES
7.2.6. F HOFFMANN-LA ROCHE
7.2.6.1. COMPANY OVERVIEW
7.2.6.2. PRODUCT LIST
7.2.6.3. STRENGTHS & CHALLENGES
7.2.7. LUPIN LIMITED
7.2.7.1. COMPANY OVERVIEW
7.2.7.2. PRODUCTS LIST
7.2.7.3. STRENGTHS & CHALLENGES
7.2.8. MERCK & CO INC
7.2.8.1. COMPANY OVERVIEW
7.2.8.2. PRODUCT LIST
7.2.8.3. STRENGTHS & CHALLENGES
7.2.9. NOVARTIS AG
7.2.9.1. COMPANY OVERVIEW
7.2.9.2. PRODUCTS LIST
7.2.9.3. STRENGTHS & CHALLENGES
7.2.10. SUN PHARMACEUTICALS INDUSTRIES LTD
7.2.10.1. COMPANY OVERVIEW
7.2.10.2. PRODUCT LIST
7.2.10.3. STRENGTHS & CHALLENGES
7.2.11. PFIZER INC
7.2.11.1. COMPANY OVERVIEW
7.2.11.2. PRODUCTS LIST
7.2.11.3. STRENGTHS & CHALLENGES
7.2.12. EISAI CO LTD
7.2.12.1. COMPANY OVERVIEW
7.2.12.2. PRODUCT LIST
7.2.12.3. STRENGTHS & CHALLENGES
7.2.13. JOHNSON & JOHNSON
7.2.13.1. COMPANY OVERVIEW
7.2.13.2. PRODUCT LIST
7.2.13.3. STRENGTHS & CHALLENGES
7.2.14. GE HEALTHCARE
7.2.14.1. COMPANY OVERVIEW
7.2.14.2. PRODUCT LIST
7.2.14.3. STRENGTHS & CHALLENGES